Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Verastem, Inc.

VSTM

Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.

Last trade $7.48
Day change -$0.22 (-2.86%)
Day range $7.43 – $8.16
Volume 1,837,626
Market cap $970M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$970.31M
Price / earnings
—
Price / book
96.06×
Price / sales
9.67×
EV / sales
9.21×
EV / EBITDA
-4.79×

Profitability

Earnings per share
-$1.42
Return on assets
-77.91%
Return on equity
-1,771.14%
Dividend yield
0%

Liquidity and leverage

Debt / equity
12.46×
Current ratio
1.93×
Quick ratio
1.91×
Cash ratio
1.67×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$159.57M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for VSTM, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$24.01M$40.08M$18.67M$17.54M$11.24M$2.14M$0$0
Cost of revenue$3.95M$4.04M$3.05M$2.61M$1.96M$446K$0$0
Gross profit$20.07M$36.04M$15.62M$14.92M$9.28M$1.69M$0$0
Selling, general and administrative$26.49M$27.41M$22.3M$24.44M$21.01M$20.67M$15.02M$10.78M
Research and development$68.81M$41.34M$38.22M$31.67M$28.99M$24.79M$29.15M$20.81M
Total operating expenses$95.29M$68.75M$60.52M$56.4M$50M$45.46M$44.17M$31.59M
Operating income-$75.22M-$32.71M-$44.9M-$41.48M-$40.72M-$43.76M-$44.17M-$31.59M
Interest expense-$212K-$360K-$382K-$415K-$319K-$212K-$192K-$1.15M
Income before taxes-$74.72M-$33.86M-$36.59M-$32.92M-$98.52M-$25.93M-$52.1M-$64.37M
Income taxes$0$816K$0$0$0$0$0$185K
Net income-$74.72M-$34.67M-$36.59M-$32.92M-$98.52M-$25.93M-$52.1M-$64.55M
Net income attributable to common shareholders-$74.72M-$34.67M-$36.59M-$32.92M-$98.52M-$25.93M-$52.1M-$64.55M
EBITDA-$74.95M-$32.43M-$44.62M-$40.76M-$40.42M-$43.64M-$44.16M-$31.58M
Basic earnings per share-$0.74-$0.35-$0.37-$0.39-$1.35-$0.39-$0.96-$1.32
Diluted earnings per share-$0.74-$0.35-$0.46-$0.43-$1.35-$0.62-$0.96-$1.32

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Clene Inc. (CLNN) Tops Q3 Earnings Estimates

Clene Inc. (CLNN) reported quarterly earnings of $0.05 per share, beating consensus estimates of a $0.46 loss, representing a +110.87% earnings surprise. However, the company missed revenue expectations with $0.06 million versus the consensus estimate, down 37.78%. The stock has underperformed the market by 35.8% year-to-date and carries a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market.

GlobeNewswire Inc.

Colorectal Cancer Market Set for Significant Growth During the Forecast Period (2026–2036), Due to the Emergence of Emerging Targets such as KRAS G12C, NTRK Fusions, and PIK3CA Mutations | DelveInsight

The colorectal cancer market is projected to grow significantly from 2026-2036, driven by rising incidence rates, increased disease awareness, and adoption of targeted therapies and immunotherapies. The market was valued at approximately USD 13 billion in 2025. Key growth drivers include emerging therapies targeting KRAS G12C, NTRK fusions, and PIK3CA mutations, with major pharmaceutical companies launching innovative treatments. The US accounts for the largest market share among the 7 major markets analyzed.

Zacks Investment Research

Does Verastem (VSTM) Have the Potential to Rally 79% as Wall Street Analysts Expect?

Verastem (VSTM) closed at $8.38 with a mean analyst price target of $15, suggesting 79% upside potential. The stock has gained 14.5% over the past four weeks. Analysts have revised earnings estimates higher, and VSTM holds a Zacks Rank #2 (Buy) rating. However, the article cautions that price targets should not be the sole basis for investment decisions, as they are often overly optimistic.

Zacks Investment Research

Strength Seen in Genmab (GMAB): Can Its 10.7% Jump Turn into More Strength?

Genmab shares rallied 10.7% following positive phase III trial data for epcoritamab in combination with R-CHOP for newly diagnosed diffuse large B-cell lymphoma. The stock's consensus EPS estimate was revised 8.7% higher over the past 30 days, though earnings are expected to decline 43.1% year-over-year while revenues grow 15.7%. The stock carries a Zacks Rank #3 (Hold) rating.

Zacks Investment Research

Verastem Stock Skyrockets 121% in 3 Months: Here Is Why

Verastem (VSTM) shares have surged 121% over three months, driven by accelerating sales of ovarian cancer drug Avmapki Fakzynja Co-Pack, which generated $25.1 million in Q2 2026 revenues (up 1,095% YoY), and growing optimism around VS-7375, a KRAS G12D inhibitor in phase II trials across pancreatic, lung, and colorectal cancers. The company expects VS-7375 data in October 2026 and plans FDA meetings before year-end to discuss phase III pivotal trial designs.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Jun 1, 20231-for-12reverse split